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.2012.08.0Abstract Drug discovery programs for preclinical oncology typically select compounds which
have a predilection for inducing cytotoxic effects in cancer cell lines and subsequently, for inhibiting
the growth of the transplanted cancer cells in vivo (Winquist et al., 2010). Unfortunately, the cyto-
toxic effect in vitro and inhibition of tumor growth in animal models are not the end story for cur-
ing cancer in preclinical models. The reason behind that is the exciting of small sub type of cells that
are relatively resistance to therapy and able to repopulate in vivo, called cancer stem cells (CSCs). O
leis et al. recently reported that the pluripotency gene Sox2 but not Oct4 or Nanog is expressed in
early stage of breast tumor. Furthermore, the authors demonstrated that Sox2 downregulation,
inhibited mammosphere formation and delayed tumor formation in xenograft tumor initiation
models (Leis et al., 2012). In this review, we will shed the light on the importance of Sox2 in breast
and other tissue tumorigenesis and associated aggressiveness.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Brief introduction on Sox2 and breast cancer stem cells
The cancer stem cell (CSC) hypothesis postulates that tumors
are maintained by a self-renewing CSC population that under-
goes asymmetric cell divisions to give rise both self-renewal
and cell committed to differentiate to constitute the majority
of tumor cells (McDermott and Wicha, 2010). There are now
numerous studies which have identiﬁed cancer stem cells in
leukemia (Bonnet and Dick, 1997), breast, (Al-Hajj et al.,LDH, aldehyde dehydrogen-
cogen synthase kinase
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012003) brain (Singh et al., 2003), lung (Ho et al., 2007), colon
(Ricci-Vitiani et al., 2007), and others. Tumor recurrence
and treatment failure are well known in cancer therapy and
more recently a link gets closed to cancer stem cells. CSCs
must have resistance to a given therapy to survive primary
treatment. A number of factors that may govern this phenom-
enon, including stem cell quiescence, protected niche environ-
ment, up regulated expression of xenobiotic efﬂux pumps,
enhanced anti-apoptotic and DNA repair pathways (Bomken
et al., 2010), In breast tumors, the use of neoadjuvant regimens
showed that conventional chemotherapy could lead to enrich-
ment in CSCs in treated patients as well as in xenografted mice
(Li et al., 2008; Yu et al., 2007). This suggests that many cur-
rently available cancer therapies, affected the bulk of tumor
cells, but failed to eliminate CSCs, which survive to regenerate
new tumors. The ﬁrst identiﬁcation of breast cancer stem cells
was deﬁned by the combined expression of cell surface markers
CD44+/CD24/low/lin. As few as 200 of these cells generatedier B.V. All rights reserved.
230 A. Al-Dhfyantumors in NOD/SCID mice whereas 20,000 cells that did not
display this phenotype failed to generate tumor (Al-Hajj
et al., 2003). Later studies suggested that aldehyde dehydroge-
nase 1 (ALDH-1), a detoxifying enzyme responsible for oxida-
tion of retinol to retinoic acid, may be a more potent marker of
breast CSCs (Charafe-Jauffret et al., 2010; Ginestier et al.,
2007; Morimoto et al., 2009). ALDH-1-positive breast CSCs
can induce tumor formation with as few as 500 cells. Breast
cancer cells that expressed ALDH-1 were more likely to be
estrogen receptor (ER) negative, progesterone receptor (PR)
negative, and human-epidermal growth factor receptor type
2 (HER-2) positive, and frequently developed distant metasta-
ses. ALDH-1-positive cells are resistant to conventional che-
motherapy with paclitaxel and epirubicin (Tanei et al., 2009).
Previous studies have shown that adult stem cells can be iden-
tiﬁed by a side population (SP) phenotype. A SP isolated from
the breast cancer cell line MCF7 was found to represent small
percentage of the total cell line and it contained the tumori-
genic fraction, as demonstrated by transplantation experi-
ments in NOD/SCID mice xenografts. This fraction was also
able to reconstitute the initial heterogeneity of the cell line
(Kondo et al., 2004; Patrawala et al., 2005).
The Sox gene family has been identiﬁed through their
homology to the high-mobility group (HMG) box of sex-deter-
mining region Y, and encodes transcription factors that bind
to DNA through a HMG domain and plays critical roles in
cell fate determination, differentiation and proliferation
(Kamachi et al., 2000; Wegner, 1999). Induction of Sox2 in
mouse neural stem cells blocks their differentiation, and down
regulation of Sox2 in these cells causes their premature exit
from the cell cycle and differentiation into neurons (Graham
et al., 2003). Pluripotency-associated transcription factors like
Nanog, Sox2 and Oct4 are known as regulators of embryonic
stem cell state, more recently have been identiﬁed in tumors ofInactive Wnt/β-Catenin pathway
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Figure 1 Schematic illustration of selvarious origins. The expression of embryonic transcriptional
factors in high degree may be associated with less differenti-
ated cancers (Ben-Porath et al., 2008) Sox2 was detected as
an immunogenic antigen in a signiﬁcant percentage of small
cell lung cancer patients (Gure et al., 2000), meningioma pa-
tients (Comtesse et al., 2005) and involved in invasion and
metastasis of pancreatic intraepithelial neoplasia (Sanada
et al., 2006). In the breast, Sox2 expression has been observed
in 43% of basal cell-like breast carcinomas and was found to
be strongly correlated with CK5/6, EGFR, and vimentin
immunoreactivity, suggesting that Sox2 may play a role in con-
ferring a less differentiated phenotype in these tumors (Rodri-
guez-Pinilla et al., 2007). Furthermore, Yupeng Chen et al.
reported that by screened parafﬁn-embedded mammary tissue
sections from 19 normal and 56 breast cancer patients, the
expression of Sox2 was strongly positive in breast carcinoma
cells but very weak in normal mammary epithelium cells.
Moreover, Western blotting analysis of immunoreactive Sox2
in established mammary epithelial cell lines showed that
Sox2 expression was higher in cancer but not normal breast
cell lines, suggesting a role in tumorigenesis (Chen et al., 2008).
2. Sox2 and Wnt/b-catenin self-renewal pathway
Different signaling pathways such as Wnt, Hedgehog and
Notch have been implicated in various cellular processes dur-
ing development that include differentiation, migration and
proliferation. Interestingly, dysregulation of each of these
pathways in the mammary gland generates breast cancers in
transgenic mice (Huelsken et al., 2000; Kelly et al., 2004; Sori-
ano et al., 2000; Vorechovsky et al., 1999). A critical and most
studied Wnt pathway is canonical Wnt signaling, which func-
tions by regulating the amount of the transcriptional co-activa-
tor b-catenin that controls the key developmental geneActive Wnt/β-Catenin pathway
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of secreted glycolipoprotein Wnt, cytoplasmic b-catenin pro-
tein is constantly degraded by the action of the Axin complex,
which is composed of the scaffolding protein Axin, the tumor
suppressor adenomatous polyposis coli gene product (APC),
casein kinase 1 (CK1), and glycogen synthase kinase 3
(GSK3). CK1 and GSK3 sequentially phosphorylate the ami-
no terminal region of b-catenin, resulting in b-catenin recogni-
tion by b-Trcp, an E3 ubiquitin ligase subunit, and subsequent
b-catenin ubiquitination and proteasomal degradation (He
et al., 2004). Activation of Wnt receptors blocks the GSK3b
activity and degradation of b-catenin, which is translocated
to the nucleus where it interacts with members of the T cell fac-
tor (TCF)/LEF family of HMG-domain transcription factors
to activate Wnt target gene transcription (Cadigan and Nusse,
1997; Eastman and Grosschedl, 1999) Fig. 1. As transcription
factors, all Sox proteins, including Sox2, do not stably bind to
DNA on their own. Rather, Sox proteins exert their transcrip-
tion regulation function through interacting with partner pro-
teins (Wilson and Koopman, 2002). b-catenin partnered with
Sox2 in gene transcription regulation in breast cancer cells
(Chen et al., 2008). Furthermore, blocking canonical Wnt sig-
naling within the developing retina inhibits Sox2 expression,
reduces cell proliferation, inhibits the onset of proneural gene
expression, and biases individual progenitors toward a non-
neural fate, without altering the expression of multiple progen-
itor markers and mimics the same results by blocking Sox2
(Van Raay et al., 2005).3. Sox2 associated aggressiveness and chemoresistance
The lethality of cancer is mainly caused by its properties of
metastasis, drug resistance, and subsequent recurrence (Adhik-
ari et al., 2011). High rate of mortality from breast cancer per-
sists due to the emergence of metastases in distant organs,
commonly the lungs (Minn et al., 2005). Sox2 expression was
detected in 28% of invasive breast carcinoma and high expres-
sion may promote metastatic potential (Lengerke et al., 2011).
Overexpression of Sox2 in MCF-7 breast cancer cells promotes
cell proliferation and tumorigenesis by facilitating the G1/S
transition of the cell cycle (Chen et al., 2008). The molecular
basis of Sox2 interference with breast cancer metastasis is
poorly understood. Knockdown of Sox2 in D121 lung carci-
noma cells lead to decrease in the migration of the side popu-
lation cells and upregulated apoptosis. Furthermore,
downregulation of Sox2 in D121 cells markedly suppressed
their metastatic potential in syngeneic mice (Xiang et al.,
2011). Consistent with lung carcinoma cells, Sox2 promotes
cell proliferation, DNA synthesis and increased apoptosis-
resistant properties in human prostate cancer cell line
DU145. Downregulation of Sox2 decreased tumorigenesis
and chemoresistance of DU145 cells in vivo (Jia et al., 2011).
It is worthy to note that while overexpression of Sox2 and in-
duced tumorigenesis had been demonstrated in many different
types of solid tumors, it is not in case of gastric cancer (Otsubo
et al., 2008).4. Conclusion
This work provides a basis for further studies aimed at inves-
tigating the possible way to targeting Sox2- driven cancer cellswhich may be an effective therapeutic strategy for selective kill-
ing of breast cancer stem cells.Acknowledgements
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